This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.
Aged 18-75 years old (inclusive), regardless of gender.
Part A: Patients with locally advanced or metastatic solid tumors confirmed by histology or cytology; Part B: Squamous non-small cell lung cancer.
At least one measurable tumor lesion according to RECIST v1.1.
ECOG performance score of 0-1.
Patients with active central nervous system ( CNS ) metastases.
Spinal cord compression not be cured by surgery or radiotherapy.
Subjects with uncontrollable tumor-related pain.
Moderate and severe ascites with clinical symptoms; Uncontrollable or moderate and above pleural effusion, pericardial effusion.
7
Treatment groupsSee each treatment group below.